Keynote Session: Jackie Hunter, Ph.D.
Board Director, BenevolentAI
How AI is disrupting Pharmaceutical R&D
Abstract: BenevolentAI is a British held AI company which is using AI to augment the research capabilities of drug scientists, radically changing the way R&D is done. The company spans all areas of R&D, from target identification and validation, through medicinal chemistry and lead optimization to clinical PoC. Through its proprietary platform, the company ingests vast quantities of biomedical data to augment the ability of scientists at all stages of the R&D process. This has led to significantly shorter lead optimization timelines and the generation of valuable new treatment hypotheses for serious diseases with high unmet medical need.